Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.
3.

Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Curtis JR, John A, Baser O.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1282-91. doi: 10.1002/acr.21693.

4.

Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.

Tournadre A, Pereira B, Dubost JJ, Rincheval N, Rat AC, Combe B, Soubrier M.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):296-302. Epub 2017 Jan 4.

PMID:
28079508
5.

Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

Park YB, Choi HK, Kim MY, Lee WK, Song J, Kim DK, Lee SK.

Am J Med. 2002 Aug 15;113(3):188-93.

PMID:
12208376
7.

Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.

Naerr GW, Rein P, Saely CH, Drexel H.

Vascul Pharmacol. 2016 Jun;81:22-30. doi: 10.1016/j.vph.2016.01.006. Epub 2016 Feb 21. Review.

PMID:
26903239
8.

Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.

García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X.

J Rheumatol. 2009 Jul;36(7):1365-70. doi: 10.3899/jrheum.080928. Epub 2009 Apr 15.

PMID:
19369465
9.

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.

Dahlqvist SR, Engstrand S, Berglin E, Johnson O.

Scand J Rheumatol. 2006 Mar-Apr;35(2):107-11.

PMID:
16641043
10.

Pretransplant dyslipidaemia influences primary graft dysfunction after lung transplantation.

Cottini SR, Ehlers UE, Pagnamenta A, Brandi G, Weder W, Schuepbach RA, Béchir M, Benden C.

Interact Cardiovasc Thorac Surg. 2016 Apr;22(4):402-5. doi: 10.1093/icvts/ivv295. Epub 2015 Dec 30.

PMID:
26718318
11.

Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era.

Galicia-Hernández G, Parra-Salcedo F, Ugarte-Martínez P, Contreras-Yáñez I, Ponce-de-León A, Pascual-Ramos V.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):261-9. Epub 2016 Mar 3.

PMID:
26939612
12.

Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?

Toms TE, Panoulas VF, Douglas KM, Nightingale P, Smith JP, Griffiths H, Sattar N, Symmons DP, Kitas GD.

Angiology. 2011 Feb;62(2):167-75. doi: 10.1177/0003319710373749. Epub 2010 Aug 3.

PMID:
20682616
13.

High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.

García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X.

Eur J Clin Invest. 2008 Sep;38(9):686-92. doi: 10.1111/j.1365-2362.2008.01994.x.

PMID:
18837746
14.

Radiographic outcome in Hispanic early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs.

Contreras-Yáñez I, Rull-Gabayet M, Vázquez-Lamadrid J, Pascual-Ramos V.

Eur J Radiol. 2011 Aug;79(2):e52-7. doi: 10.1016/j.ejrad.2011.03.036. Epub 2011 Apr 8.

PMID:
21477956
16.

Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.

Contreras-Yáñez I, Pascual-Ramos V.

Arthritis Res Ther. 2015 Jul 11;17:177. doi: 10.1186/s13075-015-0697-z.

17.

Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.

Filippatos TD, Derdemezis CS, Voulgari PV, Tsimihodimos V, Elisaf MS, Tselepis AD, Drosos AA.

Scand J Rheumatol. 2013;42(3):169-75. doi: 10.3109/03009742.2012.745013. Epub 2013 Jan 14.

PMID:
23311768
18.

Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis.

Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL.

Arthritis Res Ther. 2015 Mar 7;17:52. doi: 10.1186/s13075-015-0559-8.

19.

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.

Nurmohamed MT.

Vasc Health Risk Manag. 2007;3(6):845-52. Review.

20.

Supplemental Content

Support Center